Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 1 | CN | 28 Sep 2022 | |
Glioma | Preclinical | CN | 06 Jul 2023 |